EDGAR Online

REGENERON PHARMACEUTICALS INC

Reported by

POWCHIK PETER

FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 07/26/11 for the Period Ending 07/25/11

Address	777 OLD SAW MILL RIVER RD TARRYTOWN, NY 10591-6707
Telephone	9143477000
CIK	0000872589
Symbol	REGN
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	12/31

Powered By EDGAR Online
http://www.edgar-online.com
© Copyright 2011, EDGAR Online, Inc. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use.

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	2. Issuer Name **and** Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
Powchik Peter	**REGENERON PHARMACEUTICALS INC [REGN]**	_____ Director _____ 10% Owner __ **X** __ Officer (give title below) _____ Other (specify below) **SVP Clinical Development**
(Last) (First) (Middle) **777 OLD SAW MILL RIVER ROAD**	3. Date of Earliest Transaction (MM/DD/YYYY) **7/25/2011**	
(Street) **TARRYTOWN, NY 10591** (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _ **X** _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	**7/25/2011**		**M** (1)		**25000**	**A**	**$15.64**	**25000**	**D**	
Common Stock	**7/25/2011**		**F** (1)		**6949**	**D**	**$56.26**	**18051**	**D**	
Common Stock	**7/25/2011**		**F** (1)		**7074**	**D**	**$56.26**	**10977**	**D**	
Common Stock	**7/26/2011**		**S** (1)		**3577**	**D**	**$55.19** (2)	**7400**	**D**	
Common Stock	**7/26/2011**		**S** (1)		**7400**	**D**	**$54.74** (3)	**0**	**D**	
Common Stock								**1388**	**I**	**By 401(k) Plan**

Table II - Derivative Securities Beneficially Owned (*e.g.* , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non-Qualified Stock Option (right to buy)	**$15.64**	**7/25/2011**		**M** (1)			**25000**	(4)	**10/2/2016**	**Common Stock**	**25000**	(5)	**49428**	**D**	

Explanation of Responses:

(1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

(2) Represents volume-weighted average price of sales of 3,577 shares of Company stock on July 26, 2011 at prices ranging from $55.00 to $55.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 26, 2011 at each separate price.

(3) Represents volume-weighted average price of sales of 7,400 shares of Company stock on July 26, 2011 at prices ranging from $54.25 to $54.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 26, 2011 at each separate price.

(4) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

(5) Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is not applicable in this case.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Powchik Peter **777 OLD SAW MILL RIVER ROAD** **TARRYTOWN, NY 10591**			**SVP Clinical Development**	

Signatures

/s/Peter Powchik** — **7/26/2011**

** Signature of Reporting Person — Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

***** If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

****** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.